BAIYUNSHAN PH (00874) announced that on July 25, 2025, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (the "Company") held its 27th meeting of the 9th Board of Directors and approved the "Proposal on the Company's Participation in Establishing an Equity Investment Fund and Related Party Transaction." The board agreed that the Company would participate as a limited partner with its own funds of RMB 14.985 billion in establishing Guangzhou Guangyao Fund Phase II Equity Investment Partnership (Limited Partnership) (tentative name, subject to business registration, "Guangyao Phase II Fund"), accounting for 99.90% of the total committed capital contribution of Guangyao Phase II Fund. The Company signed the "Guangzhou Guangyao Fund Phase II Equity Investment Partnership (Limited Partnership) Partnership Agreement" with Guangzhou Guangyao Capital Private Fund Management Co., Ltd. ("Guangyao Capital").

Guangyao Phase II Fund completed business registration and obtained its business license on July 30, 2025, with the enterprise name "Guangzhou Guangyao Phase II Fund Equity Investment Partnership (Limited Partnership)." All partners have made their initial capital contributions according to their respective contribution ratios, totaling RMB 110 million.

Recently, the Company received notification from Guangyao Capital that Guangyao Phase II Fund completed its registration procedures with the Asset Management Association of China on August 18, 2025, and obtained the "Private Investment Fund Registration Certificate."